Screening for viral hepatitis carriage
Screening for viral hepatitis carriage

Screening for viral hepatitis carriage

Best Pract Res Clin Obstet Gynaecol. 2024 Jun 17:102523. doi: 10.1016/j.bpobgyn.2024.102523. Online ahead of print.

ABSTRACT

Viral hepatitis during pregnancy is common globally. In this review, we focus on the antenatal screen for hepatitis A, B, C and E, the prevention of mother-to-child transmission (MTCT) of hepatitis B and C, and the management of hepatitis A, B, C and E during pregnancy. Neonatal timely administration of hepatitis B immunoglobulin and hepatitis B vaccine is the cornerstone for preventing MTCT of hepatitis B virus (HBV), and perinatal antiviral prophylaxis with tenofovir disoproxil fumarate in mothers with positive HBeAg or HBV DNA >2 × 105 IU/ml also plays important roles in further reducing MTCT. Avoidance of risk practices in managing labor and delivery process of women with HCV infection may be useful to reduce MTCT of HCV. Early recognition of severe hepatic injury or liver failure associated with hepatitis viruses by regular liver function tests is critical to prevent maternal mortality associated with hepatitis.

PMID:38908915 | DOI:10.1016/j.bpobgyn.2024.102523